Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…
- The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging…
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced…
June 13, 2025 09:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) --…
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in…
RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital & Research…
Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results…
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the…